Skip to main content
Log in

Antibody Levels to Bordetella pertussis and Neisseria meningitidis in Immunodeficient Patients Receiving Immunoglobulin Replacement Therapy

  • Original Research
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Purpose

Patients with antibody deficiency rely on immunoglobulin products for protection against many vaccine-preventable diseases. We measured antibody titers against Bordetella pertussis and Neisseria meningitidis in patients receiving immunoglobulin (IG) therapy to determine if they have any protection against infections from these organisms.

Methods

In an unblinded, prospective assessment we measured antibody titers against B. pertussis filamentous hemagglutinin (FHA) and pertussis toxin (PT) antigens and N. meningitidis serogroups A, C, W-135, and Y in patients receiving immunoglobulin therapy for primary immune deficiency (PI). We measured steady state levels in patients receiving subcutaneous immunoglobulin therapy while in patients receiving intravenous immunoglobulin therapy we measured titers immediately before and after infusion to more clearly define the contribution of the infused product.

Results

Thirty subjects, 17 females and 13 males, participated in the study, 22 were receiving intravenous IG products and 8 were receiving subcutaneous IG products. Diagnoses included common variable immunodeficiency in 12, combined immunodeficiency in 6, specific antibody deficiency in 6, X-linked agammaglobulinemia in 4 and ataxia telangiectasia and hyper-IgE syndrome in one each. All subjects had detectable IgG antibodies against the pertussis antigens measured and most had antibody to the meningococcus serotypes measured. However, only 26.6 % had protective levels (>= 2 mcg/mL) against serogroup C at trough or steady state.

Conclusions

Patients receiving immunoglobulin therapy have antibodies against B. pertussis and most of them have antibodies against the four measured serogroups of N. meningitidis. There is significant variability in the levels of antibody between patients and the low titers against group C may suggest a role for active immunization in those who may respond to conjugated polysaccharide vaccine administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maranich AM, Rajnik M. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations. Pediatrics. 2009;124:e484–8.

    Article  PubMed  Google Scholar 

  2. Farcet MR, Planitzer CB, Stein O, Modrof J, Kreil TR. Hepatitis a virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol. 2010;125:198–202.

    Article  CAS  PubMed  Google Scholar 

  3. Code of Federal Regulations, 21 CFR 640.104 - Potency

  4. Lear S, Eren E, Findlow J, Borrow R, Webster D, Jolles S. Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin. J Clin Pathol. 2006;59:1191–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–92.

    Article  CAS  PubMed  Google Scholar 

  6. Prince HE, Lapé-Nixon M, Matud J. Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies. Clin Vaccine Immunol. 2006;13:266–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16:1901–6.

    Article  CAS  PubMed  Google Scholar 

  9. Peltola H, Mäkelä PH, Käyhty H, et al. Clinical efficacy of meningococcus group a capsular polysaccharide vaccine in children 3 months to 5 years of age. N Engl J Med. 1977;297:686–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported in part by the Jeffrey Modell foundation and the NIH NCRR CTSI GRANT 1UL1RR031986 and was performed at the CTSI at Children’s Hospital Los Angeles.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph A. Church.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adam, E., Church, J.A. Antibody Levels to Bordetella pertussis and Neisseria meningitidis in Immunodeficient Patients Receiving Immunoglobulin Replacement Therapy. J Clin Immunol 35, 213–217 (2015). https://doi.org/10.1007/s10875-015-0131-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-015-0131-y

Keywords

Navigation